BioNexus Historical Balance Sheet

BGLC Stock

USD 2.77 0.06 2.21%

Trend analysis of BioNexus Gene Lab balance sheet accounts such as Total Current Liabilities of 1.5 M, Total Stockholder Equity of 5 M or Net Tangible Assets of 8.7 M provides information on BioNexus Gene's total assets, liabilities, and equity, which is the actual value of BioNexus Gene Lab to its prevalent stockholders. By breaking down trends over time using BioNexus Gene balance sheet statements, investors will see what precisely the company owns and what it owes to creditors or other parties at the end of each accounting year.

Cash Flow Balance Sheet Income Statement

Covid

Financial Statement Analysis is much more than just reviewing and examining BioNexus Gene Lab latest accounting reports to predict its past. Macroaxis encourages investors to analyze financial statements over time for various trends across multiple indicators and accounts to determine whether BioNexus Gene Lab is a good buy for the upcoming year.

BioNexus Gene Inventory

860,373

Build AI portfolio with BioNexus Stock

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

About BioNexus Balance Sheet Analysis

Balance Sheet is a snapshot of the financial position of BioNexus Gene Lab at a specified time, usually calculated after every quarter, six months, or one year. BioNexus Gene Balance Sheet has two main parts: assets and liabilities. Liabilities are the debts or obligations of BioNexus Gene and are divided into current liabilities and long term liabilities. An asset, on the other hand, is anything of value that can be converted into cash and which BioNexus currently owns. An asset can also be divided into two categories, current and non-current.

BioNexus Gene Balance Sheet Chart

At present, BioNexus Gene's Accounts Payable is projected to increase significantly based on the last few years of reporting. The current year's Cash And Short Term Investments is expected to grow to about 2.1 M, whereas Total Assets are forecasted to decline to about 6.7 M.

Total Assets Total Current Liabilities Accounts Payable Cash And Short Term Investments

Add Fundamental

Total Assets

Total assets refers to the total amount of BioNexus Gene assets owned. Assets are items that have some economic value and are expended over time to create a benefit for the owner. These assets are usually recorded in BioNexus Gene Lab books under different categories such as cash, marketable securities, accounts receivable,prepaid expenses, inventory, fixed assets, intangible assets, other assets, marketable securities, accounts receivable, prepaid expenses and others. The total value of all owned resources that are expected to provide future economic benefits to the business, including cash, investments, accounts receivable, inventory, property, plant, equipment, and intangible assets.

Total Current Liabilities

Total Current Liabilities is an item on BioNexus Gene balance sheet that include short term debt, accounts payable, accrued salaries payable, payroll taxes payable, accrued liabilities and other debts. Total Current Liabilities of BioNexus Gene Lab are important to investors because some useful performance ratios such as Current Ratio and Quick Ratio require Total Current Liabilities to be accurate. The total amount of liabilities that a company is expected to pay within one year, including debts, accounts payable, and other short-term financial obligations.

Accounts Payable

An accounting item on the balance sheet that represents BioNexus Gene obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of BioNexus Gene Lab are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Cash And Short Term Investments

Short Term Investments is an account in the current assets section of BioNexus Gene Lab balance sheet. This account contains BioNexus Gene investments that will expire within one year. These investments include stocks and bonds that can be liquidated by BioNexus Gene Lab fairly quickly. The sum of a company's cash on hand, including bank deposits and short-term, highly liquid investments that are easily convertible to known amounts of cash.

Most accounts from BioNexus Gene's balance sheet are interrelated and interconnected. However, analyzing balance sheet accounts one by one will only give a small insight into BioNexus Gene Lab current financial condition. On the other hand, looking into the entire matrix of balance sheet accounts, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in BioNexus Gene Lab. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in bureau of economic analysis.

	2022	2023	2024	2025 (projected)
Total Current Liabilities	2.0M	1.6M	2.0M	1.5M
Total Assets	8.7M	11.4M	10.4M	6.7M

Total Current Liabilities Total Assets

BioNexus Gene balance sheet Correlations

	Total Assets	Total Current Liabilities	Total Stockholder Equity	Net Tangible Assets	Net Debt	Retained Earnings	Accounts Payable	Cash	Cash And Short Term Investments	Common Stock Shares Outstanding	Other Stockholder Equity	Total Liab	Total Current Assets	Common Stock	Other Current Liab	Other Liab	Property Plant And Equipment Net	Non Current Assets Total	Net Receivables	Short Term Investments	Non Current Liabilities Total	Inventory	Other Current Assets	Property Plant Equipment	Short Long Term Debt Total	Capital Lease Obligations
Total Assets		0.91	0.99	0.96	-0.9	-0.27	0.57	0.91	0.85	0.35	-0.73	0.92	1.0	0.94	-0.75	0.78	0.99	0.98	0.82	0.24	0.87	0.97	0.59	0.98	0.57	0.57
Total Current Liabilities	0.91		0.85	0.86	-0.72	-0.07	0.53	0.73	0.69	0.34	-0.72	1.0	0.93	0.79	-0.65	0.58	0.93	0.84	0.93	0.24	0.68	0.9	0.75	0.91	0.44	0.44
Total Stockholder Equity	0.99	0.85		0.95	-0.92	-0.31	0.56	0.94	0.87	0.34	-0.71	0.87	0.99	0.95	-0.76	0.81	0.97	0.99	0.76	0.24	0.89	0.96	0.52	0.97	0.59	0.59
Net Tangible Assets	0.96	0.86	0.95		-0.89	-0.39	0.57	0.85	0.77	0.41	-0.72	0.87	0.95	0.91	-0.78	0.87	0.96	0.95	0.81	0.03	0.88	0.95	0.57	0.93	0.56	0.56
Net Debt	-0.9	-0.72	-0.92	-0.89		0.6	-0.48	-0.98	-0.91	-0.16	0.71	-0.73	-0.88	-0.94	0.69	-0.8	-0.85	-0.91	-0.53	-0.09	-0.89	-0.82	-0.43	-0.82	-0.7	-0.7
Retained Earnings	-0.27	-0.07	-0.31	-0.39	0.6		-0.01	-0.51	-0.28	0.2	0.19	-0.09	-0.25	-0.44	0.15	-0.5	-0.23	-0.34	0.15	0.61	-0.56	-0.23	-0.12	-0.19	-0.79	-0.79
Accounts Payable	0.57	0.53	0.56	0.57	-0.48	-0.01		0.5	0.52	0.19	-0.81	0.55	0.58	0.64	-0.94	0.24	0.55	0.46	0.54	0.27	0.67	0.49	0.51	0.53	0.23	0.23
Cash	0.91	0.73	0.94	0.85	-0.98	-0.51	0.5		0.92	0.15	-0.71	0.74	0.9	0.96	-0.69	0.74	0.86	0.92	0.52	0.21	0.91	0.83	0.43	0.86	0.71	0.71
Cash And Short Term Investments	0.85	0.69	0.87	0.77	-0.91	-0.28	0.52	0.92		0.16	-0.71	0.7	0.84	0.85	-0.69	0.62	0.79	0.84	0.53	0.5	0.73	0.74	0.33	0.77	0.41	0.41
Common Stock Shares Outstanding	0.35	0.34	0.34	0.41	-0.16	0.2	0.19	0.15	0.16		-0.29	0.34	0.32	0.28	-0.32	0.44	0.38	0.41	0.46	0.1	0.22	0.32	0.17	0.4	-0.21	-0.21
Other Stockholder Equity	-0.73	-0.72	-0.71	-0.72	0.71	0.19	-0.81	-0.71	-0.71	-0.29		-0.73	-0.74	-0.85	0.87	-0.53	-0.68	-0.66	-0.57	-0.2	-0.75	-0.64	-0.41	-0.66	-0.33	-0.33
Total Liab	0.92	1.0	0.87	0.87	-0.73	-0.09	0.55	0.74	0.7	0.34	-0.73		0.94	0.81	-0.66	0.6	0.94	0.85	0.92	0.23	0.71	0.91	0.75	0.92	0.45	0.45
Total Current Assets	1.0	0.93	0.99	0.95	-0.88	-0.25	0.58	0.9	0.84	0.32	-0.74	0.94		0.93	-0.76	0.75	0.99	0.97	0.84	0.25	0.86	0.97	0.62	0.98	0.57	0.57
Common Stock	0.94	0.79	0.95	0.91	-0.94	-0.44	0.64	0.96	0.85	0.28	-0.85	0.81	0.93		-0.81	0.78	0.89	0.92	0.63	0.13	0.95	0.87	0.48	0.89	0.66	0.66
Other Current Liab	-0.75	-0.65	-0.76	-0.78	0.69	0.15	-0.94	-0.69	-0.69	-0.32	0.87	-0.66	-0.76	-0.81		-0.54	-0.73	-0.69	-0.64	-0.24	-0.81	-0.69	-0.45	-0.71	-0.32	-0.32
Other Liab	0.78	0.58	0.81	0.87	-0.8	-0.5	0.24	0.74	0.62	0.44	-0.53	0.6	0.75	0.78	-0.54		0.77	0.86	0.53	-0.15	0.74	0.81	0.15	0.75	0.48	0.48
Property Plant And Equipment Net	0.99	0.93	0.97	0.96	-0.85	-0.23	0.55	0.86	0.79	0.38	-0.68	0.94	0.99	0.89	-0.73	0.77		0.97	0.88	0.2	0.84	0.98	0.65	0.99	0.55	0.55
Non Current Assets Total	0.98	0.84	0.99	0.95	-0.91	-0.34	0.46	0.92	0.84	0.41	-0.66	0.85	0.97	0.92	-0.69	0.86	0.97		0.75	0.19	0.86	0.95	0.49	0.97	0.57	0.57
Net Receivables	0.82	0.93	0.76	0.81	-0.53	0.15	0.54	0.52	0.53	0.46	-0.57	0.92	0.84	0.63	-0.64	0.53	0.88	0.75		0.25	0.55	0.86	0.72	0.86	0.22	0.22
Short Term Investments	0.24	0.24	0.24	0.03	-0.09	0.61	0.27	0.21	0.5	0.1	-0.2	0.23	0.25	0.13	-0.24	-0.15	0.2	0.19	0.25		-0.04	0.15	0.0	0.23	-0.38	-0.38
Non Current Liabilities Total	0.87	0.68	0.89	0.88	-0.89	-0.56	0.67	0.91	0.73	0.22	-0.75	0.71	0.86	0.95	-0.81	0.74	0.84	0.86	0.55	-0.04		0.82	0.52	0.84	0.77	0.77
Inventory	0.97	0.9	0.96	0.95	-0.82	-0.23	0.49	0.83	0.74	0.32	-0.64	0.91	0.97	0.87	-0.69	0.81	0.98	0.95	0.86	0.15	0.82		0.56	0.98	0.55	0.55
Other Current Assets	0.59	0.75	0.52	0.57	-0.43	-0.12	0.51	0.43	0.33	0.17	-0.41	0.75	0.62	0.48	-0.45	0.15	0.65	0.49	0.72	0.0	0.52	0.56		0.64	0.52	0.52
Property Plant Equipment	0.98	0.91	0.97	0.93	-0.82	-0.19	0.53	0.86	0.77	0.4	-0.66	0.92	0.98	0.89	-0.71	0.75	0.99	0.97	0.86	0.23	0.84	0.98	0.64		0.56	0.56
Short Long Term Debt Total	0.57	0.44	0.59	0.56	-0.7	-0.79	0.23	0.71	0.41	-0.21	-0.33	0.45	0.57	0.66	-0.32	0.48	0.55	0.57	0.22	-0.38	0.77	0.55	0.52	0.56		1.0
Capital Lease Obligations	0.57	0.44	0.59	0.56	-0.7	-0.79	0.23	0.71	0.41	-0.21	-0.33	0.45	0.57	0.66	-0.32	0.48	0.55	0.57	0.22	-0.38	0.77	0.55	0.52	0.56	1.0

Click cells to compare fundamentals

BioNexus Gene Account Relationship Matchups

BioNexus Gene balance sheet Accounts

	2020	2021	2022	2023	2024	2025 (projected)
Total Assets	10.1M	9.6M	8.7M	11.4M	10.4M	6.7M
Total Current Liabilities	3.4M	2.3M	2.0M	1.6M	2.0M	1.5M
Total Stockholder Equity	6.7M	7.2M	6.7M	9.7M	8.3M	5.0M
Net Tangible Assets	1.5M	1.1M	6.7M	7.2M	8.3M	8.7M
Net Debt	(2.7M)	(2.0M)	(2.1M)	(5.8M)	(4.2M)	(4.0M)
Retained Earnings	760.8K	1.5M	1.2M	(1.8M)	(3.4M)	(3.3M)
Cash	2.8M	2.1M	2.1M	5.9M	4.4M	2.5M
Cash And Short Term Investments	2.8M	2.1M	2.1M	5.9M	1.6M	2.1M
Common Stock Shares Outstanding	857.7K	1.4M	14.4M	158.8K	1.8M	2.6M
Liabilities And Stockholders Equity	10.1M	9.6M	8.7M	11.4M	10.4M	6.7M
Total Liab	3.5M	2.4M	2.1M	1.7M	2.1M	1.6M
Total Current Assets	8.0M	7.1M	6.0M	8.0M	7.4M	4.9M
Accumulated Other Comprehensive Income	133.7K	(100.3K)	(409.1K)	(677.3K)	(555K)	(527.3K)
Other Current Liab	50.1K	32.3K	103.4K	180.9K	301.3K	180.5K
Property Plant And Equipment Net	1.8M	1.7M	1.6M	1.7M	1.7M	1.3M
Non Current Assets Total	2.1M	2.4M	2.7M	3.4M	3.0M	2.0M
Net Receivables	4.0M	3.4M	2.9M	857.3K	1.6M	1.8M
Short Term Investments	2.1M	1.5M	1.5M	3.3M	(2.8M)	(2.7M)
Non Current Liabilities Total	79.5K	65.9K	71.1K	111.0K	159.7K	84.8K
Inventory	1.2M	1.5M	977.8K	1.1M	1.4M	860.4K
Other Current Assets	6.1M	147.1K	1.5M	122.4K	2.9M	1.6M
Property Plant Equipment	341.8K	336.5K	1.8M	1.6M	1.9M	961.7K
Short Long Term Debt Total	123.4K	76.9K	56.8K	133.4K	210.6K	121.4K
Capital Lease Obligations	123.4K	76.9K	56.8K	133.4K	210.6K	121.4K
Net Invested Capital	6.7M	7.2M	6.7M	9.7M	8.3M	6.5M
Long Term Investments	281.7K	749.0K	1.2M	1.7M	1.3M	812.6K
Net Working Capital	4.6M	4.8M	4.0M	6.4M	5.5M	4.3M
Short Term Debt	91.5K	79.0K	16.6K	47.8K	101.6K	66.0K
Property Plant And Equipment Gross	1.8M	1.6M	2.2M	2.3M	2.5M	2.0M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

F	Ford Motor
MSFT	Microsoft
GM	General Motors

When determining whether BioNexus Gene Lab offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNexus Gene's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bionexus Gene Lab Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bionexus Gene Lab Stock:

How To Invest In BioNexus

Details

Is BioNexus Stock a good investment?

Details

What is BioNexus Gene's Net Worth?

Details

Largest Specialty Chemicals Companies

View

Largest Basic Materials Companies

View

You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.

Is Specialty Chemicals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioNexus Gene. If investors know BioNexus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioNexus Gene listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Quarterly Earnings Growth

(0.95)

Earnings Share

(1.19)

Revenue Per Share

5.178

Quarterly Revenue Growth

(0.10)

Return On Assets

(0.14)

The market value of BioNexus Gene Lab is measured differently than its book value, which is the value of BioNexus that is recorded on the company's balance sheet. Investors also form their own opinion of BioNexus Gene's value that differs from its market value or its book value, called intrinsic value, which is BioNexus Gene's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioNexus Gene's market value can be influenced by many factors that don't directly affect BioNexus Gene's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between BioNexus Gene's value and its price as these two are different measures arrived at by different means. Investors typically determine if BioNexus Gene is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioNexus Gene's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2025 Macroaxis LLC

BioNexus Historical Balance Sheet

BioNexus Gene Inventory

860,373

About BioNexus Balance Sheet Analysis

BioNexus Gene Balance Sheet Chart

Total Assets

Total Current Liabilities

Accounts Payable

Cash And Short Term Investments

BioNexus Gene balance sheet Correlations

BioNexus Gene Account Relationship Matchups

High Positive Relationship

High Negative Relationship

BioNexus Gene balance sheet Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Total Current Assets	+ 1.0	Total Assets
Total Liab	+ 1.0	Total Current Liabilities
Capital Lease Obligations	+ 1.0	Short Long Term Debt Total
Total Stockholder Equity	+ 0.99	Total Assets
Property Plant And Equipment Net	+ 0.99	Total Assets
Total Current Assets	+ 0.99	Total Stockholder Equity

Cash	- 0.98	Net Debt
Other Current Liab	- 0.94	Accounts Payable
Common Stock	- 0.94	Net Debt
Net Debt	- 0.92	Total Stockholder Equity
Non Current Assets Total	- 0.91	Net Debt
Cash And Short Term Investments	- 0.91	Net Debt